The CEO of Kite Pharma plans to initiate early conversations with insurers, even before the launch of a clinical trial of their experimental drug, to ensure smooth sailing once the product is approved and launched.
Kite Pharma Inc plans to open conversations with insurers this year to lay the groundwork for an experimental cancer treatment that could cost hundreds of thousands of dollars if it works and is approved by regulators, top executives said this week.
The possible treatment has yet to start a broad clinical trial, but the urgency comes as biotech and pharma companies consider how to navigate pushback by health insurers against GileadSciences
Inc on the price of its hepatitis C treatment.
Read the full report on Reuters: http://reut.rs/1ukdYtz
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen